Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Regeneron Pharmaceuticals Inc (NASDAQ REGN) traded down $18.10 during mid-day trading on Tuesday, hitting $324.57. The company had a trading volume of 1,403,615 shares, compared to its average volume of 1,066,957. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. The stock has a market cap of $34,890.00, a P/E ratio of 31.45, a PEG ratio of 1.27 and a beta of 1.47. Regeneron Pharmaceuticals Inc has a 52-week low of $314.99 and a 52-week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.18 by $1.05. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.04 EPS. sell-side analysts expect that Regeneron Pharmaceuticals Inc will post 14.13 EPS for the current fiscal year.

REGN has been the topic of a number of recent research reports. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Barclays lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their price objective for the stock from $450.00 to $395.00 in a research note on Friday, October 20th. Guggenheim reissued a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Finally, Robert W. Baird raised Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Friday, November 3rd. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $463.19.

Several hedge funds have recently bought and sold shares of the stock. Global X MANAGEMENT CO LLC raised its holdings in shares of Regeneron Pharmaceuticals by 10.7% in the 3rd quarter. Global X MANAGEMENT CO LLC now owns 1,334 shares of the biopharmaceutical company’s stock valued at $596,000 after buying an additional 129 shares during the period. King Luther Capital Management Corp raised its holdings in shares of Regeneron Pharmaceuticals by 21.3% in the 3rd quarter. King Luther Capital Management Corp now owns 825 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 145 shares during the period. Advantus Capital Management Inc raised its holdings in shares of Regeneron Pharmaceuticals by 1.9% in the 3rd quarter. Advantus Capital Management Inc now owns 7,885 shares of the biopharmaceutical company’s stock valued at $3,526,000 after buying an additional 148 shares during the period. BTIM Corp. raised its holdings in shares of Regeneron Pharmaceuticals by 14.3% in the 4th quarter. BTIM Corp. now owns 1,200 shares of the biopharmaceutical company’s stock valued at $451,000 after buying an additional 150 shares during the period. Finally, Nomura Asset Management Co. Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 0.9% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 17,010 shares of the biopharmaceutical company’s stock valued at $7,606,000 after buying an additional 151 shares during the period. Hedge funds and other institutional investors own 65.89% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Joseph L. Goldstein Sells 1,000 Shares of Regeneron Pharmaceuticals Inc (REGN) Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/02/13/joseph-l-goldstein-sells-1000-shares-of-regeneron-pharmaceuticals-inc-regn-stock.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.